Condition: Gastric Cancer · Diffuse Type Carcinoma · Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
The regimen of Albumin paclitaxel+SOX+BEV neoadjuvant therapy lasted for 6 cycles, during which PD-1 monoclonal antibody therapy was interspersed for 4 cycles for locally advanced diffuse gastric cancer.
This description comes directly from the study's public registry record.
Chunxia Du, MD · 87787121 · retinadcx@vip.163.com
Always discuss trial participation with your own doctor first.
| Cancer hospital，Chinese acadamy of medical sciences | Beijing, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06371586